Oxford Biomedica welcomes new chief financial officer

Oxford Biomedica, a cell and gene therapy firm, has welcomed Dr Lucinda Crabtree as chief financial officer (CFO) following the announcement of her appointment this July.

Lucinda had been serving as CFO of MorphoSys AG, where she led a finance team across the US and Germany until the company’s acquisition by Novartis.

Before that, she was CFO at Autolus Therapeutics, a Nasdaq listed clinical stage biopharmaceutical company.

Lucinda also brings extensive experience from the investment and banking sectors, having held roles at institutions including Woodford Investment Management, Goldman Sachs, and Jefferies.

Dr Frank Mathias, CEO of Oxford Biomedica, said: “We’re thrilled that Lucy has joined Oxford Biomedica as our new CFO and board member today.

“Lucy brings a wealth of experience from her roles as a CFO and time as a healthcare investor and equity research analyst.

“Her experience will be invaluable as we grow our international position as a leading cell and gene therapy contract development and manufacturing organisation (CDMO).”

Lucinda added: “I’m excited to be joining Oxford Biomedica as CFO today.

“I firmly believe in the company’s growth strategy and am looking forward to working with the board and the rest of the leadership team.

“Together, I’m confident we’ll fulfil our mission of enabling our growing client base to deliver life-changing therapies to patients.”